Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1280157rdf:typepubmed:Citationlld:pubmed
pubmed-article:1280157lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C0009013lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:1280157lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:1280157pubmed:issue3lld:pubmed
pubmed-article:1280157pubmed:dateCreated1992-12-30lld:pubmed
pubmed-article:1280157pubmed:abstractTextTumor clones isolated from the same subcutaneous metastatic lesion of a melanoma patient were used to investigate the potential role of beta 1-integrins (VLA) in the lysability of neoplastic cells by autologous CD3+, WT31+, CD8+ cytotoxic T-cell clones. Phenotypic analysis of melanoma clones for expression of VLA molecules revealed a subset of clones with high expression of VLA-2, VLA-5, and VLA-6. This subset was also characterized by increased susceptibility to lysis by tumor-specific and nonspecific cytotoxic T-lymphocytes from either TILs or PBLs. Blocking assays with monoclonal antibodies indicated that anti-VLA-2, -5, and -6 antibodies could significantly reduce the lysis of VLA-2+, VLA-5+, and VLA-6+ melanoma clones by either specific and nonspecific CTLs. By contrast, no inhibition was seen on lysis of VLA-2-, VLA-5-, and VLA-6-negative tumor cells. These data indicate that expression of some beta 1-integrins on human melanoma can influence the specific and nonspecific T-cell-mediated recognition of neoplastic cells.lld:pubmed
pubmed-article:1280157pubmed:languageenglld:pubmed
pubmed-article:1280157pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:citationSubsetIMlld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280157pubmed:statusMEDLINElld:pubmed
pubmed-article:1280157pubmed:monthOctlld:pubmed
pubmed-article:1280157pubmed:issn1053-8550lld:pubmed
pubmed-article:1280157pubmed:authorpubmed-author:ParmianiGGlld:pubmed
pubmed-article:1280157pubmed:authorpubmed-author:AnichiniAAlld:pubmed
pubmed-article:1280157pubmed:authorpubmed-author:MortariniRRlld:pubmed
pubmed-article:1280157pubmed:issnTypePrintlld:pubmed
pubmed-article:1280157pubmed:volume12lld:pubmed
pubmed-article:1280157pubmed:ownerNLMlld:pubmed
pubmed-article:1280157pubmed:authorsCompleteYlld:pubmed
pubmed-article:1280157pubmed:pagination183-6lld:pubmed
pubmed-article:1280157pubmed:dateRevised2008-3-18lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:meshHeadingpubmed-meshheading:1280157-...lld:pubmed
pubmed-article:1280157pubmed:year1992lld:pubmed
pubmed-article:1280157pubmed:articleTitleBeta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones.lld:pubmed
pubmed-article:1280157pubmed:affiliationDivision of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.lld:pubmed
pubmed-article:1280157pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1280157lld:pubmed